News -CureApp, Inc.

CureApp Inc. (head office: Chuo-ku, Tokyo, President and CEO: Kota Satake) announced it starts joint-development and clinical research of "Digital Therapeutics" for hypertension with Professor Kazuomi Kario of Cardiovascular Medicine, Jichi Medical University. The clinical research explores the anti-hypertensive effects of the "Digital Therapeutics" and aims to create a novel treatment strategy for hypertension other than medication. Background CureApp Inc. aims to create a brand new treatment that is individually optimized (personalized) to achieve a higher therapeutic effect in light of mobile technology evolution. In particular, the scope of treatment encompasses patient awareness, habits and time out in the reach of conventional intervention, such as outside of hospital/clinic, at home, or out of workplace, overarching a wide variety of patients’ life. CureApp acknowledges uniqueness of patient’s individual status and aims to establish a mechanism of’ timely

CureApp and its “Digital Therapeutics︎︎”, together with NASH (Non-Alcoholic Steatohepatitis)have launched multi-center clinical trials of their Digital Therapeutics.   CureApp Co., Ltd (head office: Chuo-ku, Tokyo, President and CEO: Kohta Satake) in collaboration with Koike Kazuhiko and Assistant Professor Masaya Sato from the Department of Gastroenterology and Internal Medicine at the University of Tokyo Hospital, have been carrying out the research and development of “Digital Therapeutics”. We are pleased to inform you that we are starting multiple institutional clinical trials of the (NASH App) Digital Therapeutics, an application dedicated to the treatment of NASH (Non-Alcoholic Steatohepatitis). This research follows the results of feasibility studies that have been conducted since 2016 at the University of Tokyo Hospital. It is a novel multi institutional clinical research project that has just begun and we aim to continue to obtain evidence to impro

CureApp Satellite Session Present at the 17th World Conference on Tobacco or Health CAPE TOWN, South Africa ‒   CureApp showcased their breakthrough invention “ Smoking Cessation “ program at the 17th World Conference on Tobacco or Health (WCTOH) in Cape Town, South Africa from March 7-9, 2018. The WCTOH is the premier international forum on tobacco control that aims to foster regional and international partnerships through exchange and mentorship opportunities. This year, for the first time in its 50-year history, the event was held on the African continent. The conference brought together 2000 delegates from more than 100 countries, including researchers, academics, non-governmental organizations, civil society, scientists, healthcare professionals and public officials, working on all aspects of tobacco control. As the conference theme “ Uniting the World for a Tobacco-Free Generation” suggests, international collaboration is vital for

CureApp and HIKARI LAB have began offering the “ascureSPARX Mental Health Program”: A doctor developed application based on cognitive behavior therapy and online counseling.   CureApp Co., Ltd. (head office: Chuo-ku, Tokyo, President and CEO: Kouta Satake)  which deals with the research and development of “Treatment Applications” as medical  devices in treatment programs, together with HIKARI LAB Co., Ltd. (Head office: Chuo-ku,  Tokyo, President: Ayako Shimizu) which offers online counselling and smart phone  applications for psychological care, have joined together to begin offering the “ascureSPARX  Mental Health Program”: A program designed for corporate mental counselling through the  combination of specialized applications and online remote guidance. The “ascureSPARX Mental Health Program” is a psychological care and counseling program that combines a “doctor developed application” and “online counseling”. It provides psychological care based

To the press and whom it may concern: “ Cure App Co., Ltd. ” which conducts research and development for "Treatment Applications ® " issued a third-party allocation of new shares to a total of about 1.5 billion yen Cure App Co., Ltd. (Head office: Chuo , Tokyo. President and CEO: Kota Satake), which conducts research and development for medical treatment applications for the treatment of disorders, announced today that they are implementing a third-party allocation of new shares of over 1.5 billion yen with newly acquired investors: the ITOCHU Corporation, ITOCHU Technology Ventures, CYBERDYNE Corporation, Dai-ichi Life Insurance Co., Ltd., Mitsubishi UFJ Capital Co., Ltd., Iwashin Business Creation Capital Co., Ltd., Saison Ventures Co., Ltd. (Credit Saison corporate Venture Capital), Chibagin Capital Corporation, Mizuho Capital Corporation in addition to our existing investors, Beyond Next Ventures and

Japan’s digital health startup  CureApp  announced on Monday that it has fundraised 1.5 billion yen (about $14 million) in the latest round. This follows their  previous $3.4 million funding  from Beyond Next Ventures (BNV), Keio Innovation Initiative (KII), and SBI Investment back in February last year. In addition to existing investors BNV and KII, participating investors in this round are Itochu Corporation (TSE:8001), Itochu Technology Ventures, Cyberdine (TSE:7779), Dai-ichi Life (TSE:8750), Mitsubishi UFJ Capital, Iwagin Jigyo Souzou Capital, Saison Ventures, Chibagin Capital, and Mizuho Capital. Read here in Detail :  The Bridge